Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMT-NK and Pembrolizumab in Refractory Biliary Tract Cancer
NCT03937895Phase 2Completed
- Sponsor
- SMT bio Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SMT-NK in biliary tract cancer (BTC), sponsored by SMT bio Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 9 weeks and Objective Response Rate at 27 weeks. Started Dec 2019; status: completed.
02
Drugs
SMT-NK
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03937895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937895.